ArticleFood science & nutrition2025
Anti-Inflammatory Role of Myo-Inositol in Obesity: Suppression of TNF-α-Induced Inflammation and Monocyte Adhesion in Hypertrophic Human Adipocytes.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RAW 264.7 macrophage cell line as a metabolomic model for analyzing and understanding inflammation processes.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- In silico pharmacology and 3D-bioprinting reveal Dicranum scoparium as an inhibitor of NF-κB-induced inflammation in the 3D4/31 alveolar macrophage cell line.Journal of natural medicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation in hypertrophic adipose tissue is a key driver of obesity-related cardiometabolic diseases. Under insulin resistance conditions, insulin signaling shifts toward pro-inflammatory pathways, disrupting normal metabolic processes. Inositols (INSs), a class of carbocyclic sugars, serve as important secondary messengers in insulin signaling. This study investigates whether myo-inositol (MYO), in addition to its known insulin-sensitizing properties, also exerts anti-inflammatory effects, and thus potentially attenuates adipose tissue inflammation. Human Simpson-Golabi-Behmel syndrome (SGBS) adipocytes were treated with MYO (100 μmol/L) for 4 h before pro-inflammatory stimulation with different dymetabolic-related cytokines including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and lipopolysaccharide (LPS). Pro-inflammatory gene expression and protein secretion were assessed via qPCR, ELISA, EIA, and immunocytochemistry, while reactive oxygen species (ROS) overproduction, nuclear factor (NF)-κB activation, and mitochondrial content were assessed using specific probes and transactivation assays, respectively. Functionally, the regulation of adhesion of monocytes to inflamed adipocytes was quantified using a cell adhesion assay. MYO significantly reduced the pro-inflammatory expression and secretion of CCL-2, CXCL-10, and IL-6, resulting in reduced adhesion of monocytes to inflamed adipocytes. Additionally, MYO suppressed TNF-α-induced surface expression of ICAM-1, a critical adhesion molecule in adipose tissue inflammation. Mechanistically, MYO attenuated ROS overproduction and the related NF-κB activation, the key regulator of adipocyte inflammation, and improved the mitochondrial dysfunction, thus overall restoring adipose tissue dysfunction. Although further research is needed, these findings suggest that MYO effectively improves the inflammatory and dysmetabolic profile of hypertrophic fat cells, highlighting its potential as a therapeutic option for metabolic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.